CAS: 1254053-43-4; 6-Ethyl-3-((3-Methoxy-4-(4-(4-Methylpiperazin-1-yl)Piperidin-1-yl)Phenyl)Amino)-5-((Tetrahydro-2H-Pyran-4-yl)Amino)Pyrazine-2-Carboxamide
该化合物是一个合成有机化合物,其特点是其复杂的分子结构,包括多种功能组,如氨,甲基氧和丙基环.该化合物具有潜在的药理特性,经常在药用化学和药物开发方面加以探讨. 管状和管状动物的出现表明它可能与生物目标发生相互作用,特别是在中央...
- 英文名称6-Ethyl-3-((3-Methoxy-4-(4-(4-Methylpiperazin-1-yl)Piperidin-1-yl)Phenyl)Amino)-5-((Tetrahydro-2H-Pyran-4-yl)Amino)Pyrazine-2-Carboxamide
- 中文名称吉瑞替尼
- IUPAC名称6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide
- 其它别名Gilteritinib [who-Dd]; Gilteritinib Hcl; Gilteritinib [mi]; 1,4-Oxadiazole, 2-(O-Hydroxyphenyl)-; 2-Pyrazinecarboxamide, 6-Ethyl-3-((3-Methoxy-4-(4-(4-Methyl-1-Piperazinyl)-1-Piperidinyl)Phenyl)Amino)-5-((Tetrahydro-2H-Pyr
- CAS编号1254053-43-4
- MFCD编号:MFCD28144685
- EINECS号:107-777-6
- FDA UNII编号:66D92MGC8M
- 分子式:C29H44N8O3
- 分子量:552.72
- 产品CID: 377868
- 同类组份化合物CAS1254053-43-4 (free base)1254053-84-3 (hemifumarate)
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
- 熔点>157°C (分解)
- 沸点696.9±55.0 °C at 760 mmHg
- 闪点375.3±31.5 °C
- 密度1.2±0.1 g/cm3
- pKa:14.39±0.50(预测)
- PSA:121.11
- LogP:4.35
- 折射率1.627
- 蒸汽压0.0±2.2 mmHg at 25°C
- 溶解性Soluble In DMSO (25 mg/mL)
- 外观形态类白色至淡粉红色固体
- 储存条件-20°C
- 产品应用该化合物用作治疗患有复发性或易碎性急性髓血病(AML)的成人病人,他们患有FLT3突变(包括FL3-ITD和FLD3-TKD),经林业发展局核准的同伴诊断证实;它作为FLF3和AXL动脉的有力和选择性口服抑制剂.
MSDS等安全信息
欧盟法规
C&L通报上下游产品
3-bromo-5-chloro-6-ethylpyrazine-2-carbonitrile tetrahydro-2H-pyran-4-ylamine monohydr°Chloride合成工艺路线路线简述
- 合成目标产物 Gilteritinib 主要起始原料 4-Aminotetrahydropyran Hydrochloride
- (文献来源)合成步骤主要原料 4-Aminotetrahydropyran Hydrochloride
6-Ethyl-3-((3-Methoxy-4-(4-(4-Methylpiperazin-1-yl)Piperidin-1-yl)Phenyl)Amino)-5-((Tetrahydro-2H-Pyran-4-yl)Amino)Pyrazine-2-Carbonitrile置于双氧水,Sodium Hydroxide体系中,用 乙醇,二甲基亚砜 用作溶剂,化学反应 3.0H,以85%的收率获得吉列替尼
参考文献:一种3,5-二取代-吡嗪-2-甲酰胺化合物的合 成方法
标题:一种3,5-二取代-吡嗪-2-甲酰胺化合物的合 成方法
摘要:本发明公开了一种3,5‑二取代‑吡嗪‑2‑甲酰胺化合物的合成方法,具体的说,是一种对参与癌细胞生长的flt3‑axl的受体酪氨酸激酶具有优异抑制活性的3,5‑二取代‑吡嗪‑2‑甲酰胺化合物的合成方法,其特征是包含以下步骤:将化合物5进行水解反应,即可;本发明方法反应条件温和,操作简单,后处理简便,反应收率大幅度提高,是一条全新的可工业化的合成路线.
海关参考信息
- 2905121000-正丙醇
2905130000-正丁醇
2909110000-乙醚
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人：EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.
专利号:US-2024208898-A1
优先权日:2021-03-25
标 题 :Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
发明人：KIM JUSTIN; KANG DAHYE; CHEUNG SHELDON T
权利人:DANA FARBER CANCER INST INC
摘要:Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.
专利号:CN-116621794-A
优先权日:2023-05-22
标题:A kind of 5-benzyl-2-amino-1,3-thiazole derivatives and its synthesis method and application
专利号:CN-114656389-B
优先权日:2022-04-27
标题 :Synthesis method of 1-phenylpyrrolidine
网址: http://www.xmobio.com
电话: 0086 13524779951; 13524779951👤
销售电话:0086 13524779951; 13524779951
邮箱：sales@xmobio.com
电话: 0086 13524779951; 13524779951👤
📞上海兴默生物技术有限公司 ⚠️参考联系方式
销售电话:0086 13524779951; 13524779951
邮箱：sales@xmobio.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Yun HD, Nathan S, Larson M, Hussain MJ, Katz DA, Varma A, Miller I, Ustun C. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood Adv. 2019 Nov 26;3(22):3709-3712. doi: 10.1182/bloodadvances.2019000775.
2: Sidaway P. Gilteritinib improves outcomes in AML. Nat Rev Clin Oncol. 2019 Nov 19. doi: 10.1038/s41571-019-0305-2. [Epub ahead of print] doi: 10.1182/blood-2019-122620. doi: 10.18632/oncotarget.27222. eCollection 2019 Oct 22.
5: Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. Available from http://www.ncbi.nlm.nih.gov/books/NBK548423/ doi: 10.1186/s40364-019-0172-0. eCollection 2019.
合成参考文献
参考文献:10.1007/s11864-017-0445-5
摘要:Thomas X, Le Jeune C. Treatment of Elderly Patients With Acute Myeloid Leukemia. Current Treatment Options in Oncology. 2017 Jan 31;18(1):2. doi: 10.1007/s11864-017-0445-5.
📝 需求与反馈
尽可能描述清楚需求与问题信息
